Conservative management of endometrial hyperplasia or carcinoma with the levonorgestrel intrauterine system may be less effective in morbidly obese patients

• Endometrial hyperplasia/carcinoma regression rates with LNG-IUS were examined by BMI. • Morbidly obese patients with EH/EHA/EC are more likely to progress. • Despite addition of oral progesterone to LNG-IUS, morbid obesity increases the odds of progression.

Detalles Bibliográficos
Autores principales: Graul, Ashley, Wilson, Elise, Ko, Emily, Haggerty, Ashley F., Reed, Helen, Koelper, Nathanael, Kim, Sarah H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6148728/
https://www.ncbi.nlm.nih.gov/pubmed/30255125
http://dx.doi.org/10.1016/j.gore.2018.09.001
_version_ 1783356769040334848
author Graul, Ashley
Wilson, Elise
Ko, Emily
Haggerty, Ashley F.
Reed, Helen
Koelper, Nathanael
Kim, Sarah H.
author_facet Graul, Ashley
Wilson, Elise
Ko, Emily
Haggerty, Ashley F.
Reed, Helen
Koelper, Nathanael
Kim, Sarah H.
author_sort Graul, Ashley
collection PubMed
description • Endometrial hyperplasia/carcinoma regression rates with LNG-IUS were examined by BMI. • Morbidly obese patients with EH/EHA/EC are more likely to progress. • Despite addition of oral progesterone to LNG-IUS, morbid obesity increases the odds of progression.
format Online
Article
Text
id pubmed-6148728
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-61487282018-09-25 Conservative management of endometrial hyperplasia or carcinoma with the levonorgestrel intrauterine system may be less effective in morbidly obese patients Graul, Ashley Wilson, Elise Ko, Emily Haggerty, Ashley F. Reed, Helen Koelper, Nathanael Kim, Sarah H. Gynecol Oncol Rep Case Series • Endometrial hyperplasia/carcinoma regression rates with LNG-IUS were examined by BMI. • Morbidly obese patients with EH/EHA/EC are more likely to progress. • Despite addition of oral progesterone to LNG-IUS, morbid obesity increases the odds of progression. Elsevier 2018-09-12 /pmc/articles/PMC6148728/ /pubmed/30255125 http://dx.doi.org/10.1016/j.gore.2018.09.001 Text en © 2018 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Series
Graul, Ashley
Wilson, Elise
Ko, Emily
Haggerty, Ashley F.
Reed, Helen
Koelper, Nathanael
Kim, Sarah H.
Conservative management of endometrial hyperplasia or carcinoma with the levonorgestrel intrauterine system may be less effective in morbidly obese patients
title Conservative management of endometrial hyperplasia or carcinoma with the levonorgestrel intrauterine system may be less effective in morbidly obese patients
title_full Conservative management of endometrial hyperplasia or carcinoma with the levonorgestrel intrauterine system may be less effective in morbidly obese patients
title_fullStr Conservative management of endometrial hyperplasia or carcinoma with the levonorgestrel intrauterine system may be less effective in morbidly obese patients
title_full_unstemmed Conservative management of endometrial hyperplasia or carcinoma with the levonorgestrel intrauterine system may be less effective in morbidly obese patients
title_short Conservative management of endometrial hyperplasia or carcinoma with the levonorgestrel intrauterine system may be less effective in morbidly obese patients
title_sort conservative management of endometrial hyperplasia or carcinoma with the levonorgestrel intrauterine system may be less effective in morbidly obese patients
topic Case Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6148728/
https://www.ncbi.nlm.nih.gov/pubmed/30255125
http://dx.doi.org/10.1016/j.gore.2018.09.001
work_keys_str_mv AT graulashley conservativemanagementofendometrialhyperplasiaorcarcinomawiththelevonorgestrelintrauterinesystemmaybelesseffectiveinmorbidlyobesepatients
AT wilsonelise conservativemanagementofendometrialhyperplasiaorcarcinomawiththelevonorgestrelintrauterinesystemmaybelesseffectiveinmorbidlyobesepatients
AT koemily conservativemanagementofendometrialhyperplasiaorcarcinomawiththelevonorgestrelintrauterinesystemmaybelesseffectiveinmorbidlyobesepatients
AT haggertyashleyf conservativemanagementofendometrialhyperplasiaorcarcinomawiththelevonorgestrelintrauterinesystemmaybelesseffectiveinmorbidlyobesepatients
AT reedhelen conservativemanagementofendometrialhyperplasiaorcarcinomawiththelevonorgestrelintrauterinesystemmaybelesseffectiveinmorbidlyobesepatients
AT koelpernathanael conservativemanagementofendometrialhyperplasiaorcarcinomawiththelevonorgestrelintrauterinesystemmaybelesseffectiveinmorbidlyobesepatients
AT kimsarahh conservativemanagementofendometrialhyperplasiaorcarcinomawiththelevonorgestrelintrauterinesystemmaybelesseffectiveinmorbidlyobesepatients

Ejemplares similares